Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 7 | 2023 | 572 | 1.970 |
Why?
|
| Internet | 6 | 2020 | 469 | 1.620 |
Why?
|
| Physician-Patient Relations | 6 | 2023 | 419 | 1.470 |
Why?
|
| Text Messaging | 2 | 2023 | 86 | 1.420 |
Why?
|
| Electronic Mail | 3 | 2020 | 46 | 1.180 |
Why?
|
| Physicians | 4 | 2019 | 470 | 1.040 |
Why?
|
| Blogging | 2 | 2017 | 11 | 0.980 |
Why?
|
| Hospitalists | 1 | 2023 | 37 | 0.800 |
Why?
|
| Medical Informatics | 2 | 2020 | 73 | 0.770 |
Why?
|
| Patient Portals | 2 | 2019 | 49 | 0.740 |
Why?
|
| Transgender Persons | 1 | 2022 | 69 | 0.680 |
Why?
|
| Patient Participation | 2 | 2019 | 230 | 0.590 |
Why?
|
| Cell Phone Use | 1 | 2018 | 1 | 0.580 |
Why?
|
| Consumer Health Informatics | 1 | 2017 | 1 | 0.550 |
Why?
|
| Video Recording | 1 | 2017 | 135 | 0.510 |
Why?
|
| Social Media | 2 | 2019 | 128 | 0.510 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 598 | 0.490 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 121 | 0.490 |
Why?
|
| Pharmacies | 1 | 2016 | 36 | 0.480 |
Why?
|
| Health Behavior | 2 | 2018 | 469 | 0.470 |
Why?
|
| Consumer Health Information | 1 | 2014 | 37 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 724 | 0.440 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 475 | 0.410 |
Why?
|
| Value-Based Purchasing | 1 | 2013 | 8 | 0.410 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 102 | 0.380 |
Why?
|
| Prescription Drugs | 1 | 2012 | 51 | 0.380 |
Why?
|
| Humans | 29 | 2025 | 63445 | 0.360 |
Why?
|
| Adult | 12 | 2023 | 16824 | 0.350 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2681 | 0.340 |
Why?
|
| Primary Health Care | 1 | 2016 | 690 | 0.330 |
Why?
|
| Quality Improvement | 1 | 2013 | 443 | 0.300 |
Why?
|
| Male | 15 | 2023 | 29891 | 0.290 |
Why?
|
| Hospitals | 2 | 2022 | 393 | 0.280 |
Why?
|
| Female | 15 | 2023 | 32880 | 0.270 |
Why?
|
| Drug Costs | 3 | 2013 | 56 | 0.260 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 322 | 0.260 |
Why?
|
| United States | 9 | 2019 | 7843 | 0.240 |
Why?
|
| Consent Forms | 1 | 2025 | 15 | 0.230 |
Why?
|
| Qualitative Research | 2 | 2022 | 690 | 0.230 |
Why?
|
| Informed Consent | 1 | 2025 | 140 | 0.210 |
Why?
|
| Insurance Coverage | 3 | 2013 | 100 | 0.210 |
Why?
|
| Indiana | 2 | 2020 | 21 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2576 | 0.200 |
Why?
|
| Fasting | 1 | 2022 | 51 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 540 | 0.190 |
Why?
|
| Hypoglycemia | 1 | 2022 | 65 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2022 | 69 | 0.180 |
Why?
|
| Drugs, Generic | 2 | 2012 | 18 | 0.180 |
Why?
|
| Gender Identity | 1 | 2022 | 67 | 0.180 |
Why?
|
| Drug Utilization | 2 | 2012 | 209 | 0.170 |
Why?
|
| Emotions | 1 | 2023 | 223 | 0.170 |
Why?
|
| Middle Aged | 11 | 2022 | 17613 | 0.170 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2011 | 19 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2022 | 136 | 0.170 |
Why?
|
| Focus Groups | 1 | 2022 | 303 | 0.170 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 38 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 141 | 0.160 |
Why?
|
| Professionalism | 1 | 2019 | 11 | 0.160 |
Why?
|
| Uncompensated Care | 2 | 2009 | 5 | 0.160 |
Why?
|
| Medical Assistance | 2 | 2009 | 11 | 0.150 |
Why?
|
| Financing, Organized | 2 | 2009 | 16 | 0.150 |
Why?
|
| Inventions | 1 | 2019 | 3 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 99 | 0.150 |
Why?
|
| Aged | 9 | 2022 | 14447 | 0.150 |
Why?
|
| Trust | 1 | 2019 | 73 | 0.150 |
Why?
|
| Young Adult | 5 | 2022 | 4694 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 276 | 0.140 |
Why?
|
| Adolescent | 5 | 2022 | 6245 | 0.140 |
Why?
|
| Urban Population | 1 | 2019 | 193 | 0.140 |
Why?
|
| Health Personnel | 1 | 2022 | 367 | 0.140 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 62 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 435 | 0.140 |
Why?
|
| Personality Disorders | 1 | 2017 | 20 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 916 | 0.130 |
Why?
|
| Rural Population | 1 | 2019 | 203 | 0.130 |
Why?
|
| Personality | 1 | 2017 | 29 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 216 | 0.130 |
Why?
|
| Cost Sharing | 2 | 2013 | 15 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 361 | 0.130 |
Why?
|
| Disclosure | 3 | 2011 | 55 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 777 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 143 | 0.120 |
Why?
|
| Health Care Reform | 2 | 2013 | 87 | 0.120 |
Why?
|
| Medicare | 1 | 2019 | 612 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 192 | 0.120 |
Why?
|
| Health Expenditures | 2 | 2013 | 122 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 360 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 835 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2016 | 516 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2017 | 753 | 0.110 |
Why?
|
| Anxiety | 1 | 2017 | 425 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 761 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 65 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 54 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 326 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 383 | 0.100 |
Why?
|
| Cost Control | 1 | 2012 | 24 | 0.100 |
Why?
|
| Drug Industry | 2 | 2009 | 39 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 203 | 0.090 |
Why?
|
| Publications | 1 | 2011 | 29 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2011 | 37 | 0.090 |
Why?
|
| Developing Countries | 1 | 2011 | 94 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 66 | 0.090 |
Why?
|
| Health Resources | 1 | 2011 | 95 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 104 | 0.080 |
Why?
|
| Depression | 1 | 2017 | 894 | 0.080 |
Why?
|
| Quality of Life | 1 | 2017 | 1229 | 0.080 |
Why?
|
| Voluntary Health Agencies | 1 | 2009 | 4 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2010 | 104 | 0.080 |
Why?
|
| Financing, Government | 1 | 2009 | 31 | 0.080 |
Why?
|
| Seizures | 1 | 2010 | 143 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 84 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1364 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2009 | 168 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 564 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 220 | 0.070 |
Why?
|
| Comprehension | 1 | 2025 | 138 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 62 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 455 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 142 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2009 | 791 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5462 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 100 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 250 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 465 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 274 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 484 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 467 | 0.040 |
Why?
|
| Beneficence | 2 | 2009 | 4 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2019 | 10 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 462 | 0.040 |
Why?
|
| Culture | 1 | 2018 | 78 | 0.040 |
Why?
|
| Racism | 1 | 2019 | 88 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2009 | 311 | 0.030 |
Why?
|
| Neuroticism | 1 | 2017 | 2 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 266 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1235 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 436 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1748 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 76 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2458 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 164 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2012 | 49 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 56 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2011 | 9 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 377 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 47 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 26 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 23 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 305 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 152 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 150 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 211 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2011 | 55 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 226 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 168 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5680 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2010 | 17 | 0.020 |
Why?
|
| Altruism | 1 | 2009 | 13 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1119 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2009 | 23 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 76 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2009 | 36 | 0.020 |
Why?
|
| Government Regulation | 1 | 2009 | 41 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5354 | 0.020 |
Why?
|
| Income | 1 | 2009 | 169 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 768 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 772 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 2570 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2079 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 6658 | 0.010 |
Why?
|